OTCPK:QTVL.F

Stock Analysis Report

Executive Summary

QT Vascular Ltd., together with its subsidiaries, engages in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • QT Vascular has significant price volatility in the past 3 months.
  • QT Vascular is not covered by any analysts.

Similar Companies

Share Price & News

How has QT Vascular's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:QTVL.F

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-62.5%

OTCPK:QTVL.F

9.6%

US Medical Equipment

2.1%

US Market

QTVL.F underperformed the Medical Equipment industry which returned 9.1% over the past year.

QTVL.F underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

QTVL.FIndustryMarket
7 Day0%0.8%1.1%
30 Day-16.7%0.2%3.7%
90 Day7.1%2.7%2.3%
1 Year-62.5%-62.5%10.5%9.6%4.4%2.1%
3 Year-95.0%-95.0%69.5%64.3%47.0%37.4%
5 Yearn/a132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is QT Vascular's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is QT Vascular undervalued based on future cash flows and its price relative to the stock market?

0.39x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for QT Vascular to establish if it is available at moderate discount.

Unable to calculate intrinsic value for QT Vascular to establish if it is available at substantial discount.


Price Based on Earnings

QT Vascular is loss making, we can't compare its value to the US Medical Equipment industry average.

QT Vascular is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for QT Vascular, we can't assess if its growth is good value.


Price Based on Value of Assets

QT Vascular is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is QT Vascular expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as QT Vascular has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of QTVL.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access QT Vascular's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has QT Vascular performed over the past 5 years?

42.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

QT Vascular does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare QT Vascular's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare QT Vascular's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if QT Vascular has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if QT Vascular has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if QT Vascular improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is QT Vascular's financial position?


Financial Position Analysis

QT Vascular is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

QT Vascular's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

QT Vascular's level of debt (10.9%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 10.9% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 6.8x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Information is not available.

Unable to confirm if QT Vascular has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is QT Vascular's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate QT Vascular's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate QT Vascular's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as QT Vascular has not reported any payouts.

Unable to verify if QT Vascular's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as QT Vascular has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of QT Vascular's salary, the management and board of directors tenure and is there insider trading?

0.3yrs

Average management tenure


CEO

Eitan Konstantino (51yo)

0yrs

Tenure

0

Dr. Eitan Konstantino, Ph.D. Co-founded TriReme Medical LLC in 2005 and serves as its Chief Executive Officer & President. Dr. Konstantino is the Co-founder and Chief Executive Officer of QT Vascular Ltd.  ...


Management Age and Tenure

0.3yrs

Average Tenure

54.5yo

Average Age

The average tenure for the QT Vascular management team is less than 2 years, this suggests a new team.


Board Age and Tenure

6.1yrs

Average Tenure

53yo

Average Age

The tenure for the QT Vascular board of directors is about average.


Insider Trading

QT Vascular individual insiders have only sold shares in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$34,24301 Aug 19
Tanhum Feld
EntityIndividual
Shares11,723,000
Max PriceUS$0.0029
SellUS$329,13807 Jan 19
Three Arch Partners
EntityCompany
Shares54,728,660
Max PriceUS$0.006
BuyUS$43,25421 Dec 18
Eitan Konstantino
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares15,688,883
Max PriceUS$0.0028
SellUS$907,41421 Nov 18
Three Arch Partners
EntityCompany
Shares102,555,784
Max PriceUS$0.0088
BuyUS$96,84821 Nov 18
Eitan Konstantino
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares10,945,732
Max PriceUS$0.0088

Ownership Breakdown


Management Team

  • Eitan Konstantino (51yo)

    CEO & Executive Director

    • Tenure: 0yrs
  • Shiva Ardakani

    Senior Vice President of Quality Assurance

    • Tenure: 0yrs
  • Maria Pizzaro (57yo)

    Executive VP and VP of Research & Development

    • Tenure: 0yrs
  • Randal Farwell (60yo)

    Chief Financial Officer (Leave of Absence)

    • Tenure: 0.3yrs
  • Brosh Mimon (52yo)

    General Manager of Singapore Operations

    • Tenure: 0yrs
  • Pih Lee

    Company Secretary

    • Tenure: 3.6yrs
  • Kelvin Tong

    Co-Chief Financial Officer & Controller

    • Tenure: 0.3yrs
  • Gina La

    Co-CFO & Director of Finance

    • Tenure: 0.3yrs

Board Members

  • Mark Wan (53yo)

    Non-Independent Non-Executive Director

    • Tenure: 6.2yrs
  • Greg Casciaro (62yo)

    Independent Director

    • Tenure: 6.1yrs
  • Eitan Konstantino (51yo)

    CEO & Executive Director

    • Tenure: 0yrs
  • Amir Belson (56yo)

    Independent Chairman

    • Tenure: 1.3yrs
  • Eric Sho (49yo)

    Independent Director

    • Tenure: 4yrs

Company Information

QT Vascular Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: QT Vascular Ltd.
  • Ticker: QTVL.F
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: S$6.706m
  • Listing Market Cap: S$4.875m
  • Shares outstanding: 2.24b
  • Website: https://www.qtvascular.com

Number of Employees


Location

  • QT Vascular Ltd.
  • 3A International Business Park
  • No. 09-12 ICON @ IBP Tower B
  • Singapore
  • 609935
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
5I0Catalist (Singapore Exchange Catalist Market)YesOrdinary SharesSGSGDApr 2014
QTVL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2014

Biography

QT Vascular Ltd., together with its subsidiaries, engages in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:35
End of Day Share Price2019/09/10 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.